The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ONVO | -57.61% | -97.93% | -53.9% | -99% |
| S&P | +13.14% | +87.24% | +13.37% | +404% |
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.03M | -6.7% |
| Gross Profit | -$0.03M | 22.5% |
| Gross Margin | -110.71% | 22.6% |
| Market Cap | $7.59M | -2.9% |
| Market Cap / Employee | $0.58M | 0.0% |
| Employees | 13 | -35.0% |
| Net Income | -$2.55M | 0.2% |
| EBITDA | -$2.58M | -1.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.68M | 110.4% |
| Accounts Receivable | $0.03M | 10.3% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.17M | -73.9% |
| Short Term Debt | $0.88M | -2.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -24.12% | 115.9% |
| Return On Invested Capital | -106.43% | 9.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.38M | 10.4% |
| Operating Free Cash Flow | -$2.38M | 10.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 21.65 | 8.79 | 0.27 | 0.80 | -62.55% |
| Price to Sales | 68.07 | 29.53 | 25.92 | 54.33 | -38.90% |
| Price to Tangible Book Value | 23.04 | 8.79 | 0.27 | 0.80 | -96.88% |
| Enterprise Value to EBITDA | -2.49 | 1.94 | 1.60 | -0.77 | -74.11% |
| Return on Equity | -378.4% | -35.3% | -24.5% | -36.9% | -82.14% |
| Total Debt | $1.32M | $1.07M | $0.82M | $1.05M | -32.48% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
